6533b82cfe1ef96bd128ebcd
RESEARCH PRODUCT
Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors
Katheryn YépezSoledad ReyesRosario MenéndezLaura FecedMichael BerkMichael BerkAna FerrandoLeyre BouzasVicent Balanzá-martínezItziar EstradaAna LatorreSussy C. LuperdiEnrique ZaldivarDavid HervásPaula González-jiménezRaúl MéndezRaúl Méndezsubject
0301 basic medicineMalePediatrics030204 cardiovascular system & hematologyAnxietySevere Acute Respiratory SyndromeStress Disorders Post-Traumatic0302 clinical medicineCognitionQuality of lifeOutcome Assessment Health CareMedicineVerbal fluency testProspective StudiesSurvivorsProspective cohort studyLetter to the EditorDepression (differential diagnoses)Aged 80 and overPsychiatryDepressionMiddle AgedsequelaehumanitiesMemory Short-TermneurocognitiveAnxietyFemaleOriginal Articlemedicine.symptomAdultmedicine.medical_specialtypsychiatric morbidity03 medical and health sciencesYoung AdultSex FactorsCOVID‐19Internal MedicineHumansAgedMemory Disordersbusiness.industryWorking memorySARS-CoV-2COVID-19Original Articles030104 developmental biologyCross-Sectional Studiesquality of lifeDeliriumbusinessCognition DisordersNeurocognitiveCOVID-19 neurocognitive psychiatric morbidity quality of life sequelaedescription
BACKGROUND: The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms, and QoL in COVID-19 survivors shortly after hospital discharge. METHODS: This was a cross-sectional analysis of a prospective study of hospitalised COVID-19 survivors followed-up for 2 months after discharge. A battery of standardised instruments evaluating neurocognitive function, psychiatric morbidity, and QoL (mental and physical components) was administered by telephone. RESULTS: Of the 229 screened patients, 179 were included in the final analysis. Among survivors, the prevalence of moderately impaired immediate verbal memory and learning was 38%, delayed verbal memory (11.8%), verbal fluency (34.6%), and working memory (executive function) (6.1%), respectively. Moreover, 58.7% of patients had neurocognitive impairment in at least one function. Rates of positive screening for anxiety, depression, and post-traumatic stress disorder were 29.6%, 26.8%, and 25.1%, respectively. In addition, 39.1% of the patients had psychiatric morbidity. Low QoL for physical and mental components was detected in 44.1% and 39.1% of patients, respectively. Delirium and psychiatric morbidity were associated with neurocognitive impairment and female gender was related with psychiatric morbidity. CONCLUSION: Hospitalised COVID-19 survivors showed a considerable prevalence of neurocognitive impairment, psychiatric morbidity, and poor QoL in the short-term. It is uncertain if these impacts persist over the long-term.
year | journal | country | edition | language |
---|---|---|---|---|
2021-03-13 | Journal of Internal Medicine |